Clinical Research Directory
Browse clinical research sites, groups, and studies.
Magnesium Sulphate for Neonatal Asphyxia and Length of Hospital Stay
Sponsor: Sargodha Medical College
Summary
Neonatal asphyxia causes significant global morbidity, frequently resulting in Hypoxic-Ischemic Encephalopathy (HIE). In resource-limited settings where therapeutic hypothermia is unavailable, affordable neuroprotective options are needed. Intravenous magnesium sulphate blocks NMDA receptors, limiting cellular calcium influx and neuroinflammation. This randomized controlled trial evaluates whether adjuvant intravenous magnesium sulphate (250\\text{ mg/kg} within 6 hours of birth) reduces the duration of hospital stay and improves short-term clinical outcomes in term neonates with birth asphyxia.
Official title: Use of Magnesium Sulphate in Neonatal Asphyxia and Its Effect on Duration of Hospital Stay
Key Details
Gender
All
Age Range
Any - 24 Hours
Study Type
INTERVENTIONAL
Enrollment
72
Start Date
2026-11-01
Completion Date
2027-07-01
Last Updated
2026-09-23
Healthy Volunteers
No
Interventions
Magnesium sulphate
Intravenous infusion of Magnesium Sulphate at a dose of 250\\text{ mg/kg} administered over 30\\text{--}60 minutes within 6 hours of birth
Supportive care and standard neonatal intensive care unit care
Standard clinical supportive care including prompt resuscitation, maintenance of adequate ventilation, correction of metabolic abnormalities, and management of complications without Magnesium Sulphate.